Point72 Asset Management L.P. Buys Shares of 3,025,664 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Share on StockTwits

Point72 Asset Management L.P. purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,025,664 shares of the biopharmaceutical company’s stock, valued at approximately $37,760,000. Point72 Asset Management L.P. owned approximately 1.19% of Amicus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the business. Marshall Wace LLP raised its stake in shares of Amicus Therapeutics by 339.2% during the second quarter. Marshall Wace LLP now owns 742,236 shares of the biopharmaceutical company’s stock worth $9,263,000 after acquiring an additional 573,235 shares in the last quarter. Nomura Holdings Inc. purchased a new position in shares of Amicus Therapeutics in the second quarter worth $1,025,000. Morgan Stanley increased its stake in shares of Amicus Therapeutics by 64.6% in the second quarter. Morgan Stanley now owns 6,482,718 shares of the biopharmaceutical company’s stock worth $80,904,000 after buying an additional 2,543,211 shares during the period. Man Group plc increased its stake in shares of Amicus Therapeutics by 115.5% in the second quarter. Man Group plc now owns 291,361 shares of the biopharmaceutical company’s stock worth $3,636,000 after buying an additional 156,176 shares during the period. Finally, Novo Holdings A S increased its stake in shares of Amicus Therapeutics by 24.1% in the second quarter. Novo Holdings A S now owns 2,317,870 shares of the biopharmaceutical company’s stock worth $28,927,000 after buying an additional 450,000 shares during the period.

Several research analysts recently commented on FOLD shares. BidaskClub downgraded shares of Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Amicus Therapeutics in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $19.00 price target (down previously from $20.00) on shares of Amicus Therapeutics in a report on Wednesday, June 5th. Cowen reiterated a “buy” rating and issued a $31.00 price target on shares of Amicus Therapeutics in a report on Thursday, August 1st. Finally, ValuEngine cut shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Buy” and an average price target of $18.06.

In other news, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $12.54, for a total transaction of $250,800.00. Following the completion of the sale, the chief executive officer now owns 770,194 shares of the company’s stock, valued at approximately $9,658,232.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Burke W. Whitman purchased 4,945 shares of Amicus Therapeutics stock in a transaction dated Friday, August 23rd. The shares were acquired at an average cost of $10.07 per share, with a total value of $49,796.15. Following the transaction, the director now directly owns 21,612 shares in the company, valued at $217,632.84. The disclosure for this purchase can be found here. Insiders have sold a total of 60,000 shares of company stock valued at $701,200 in the last ninety days. Insiders own 2.50% of the company’s stock.

NASDAQ:FOLD traded down $0.17 during mid-day trading on Friday, reaching $9.45. The company’s stock had a trading volume of 4,004,310 shares, compared to its average volume of 3,611,713. Amicus Therapeutics, Inc. has a 12-month low of $8.27 and a 12-month high of $14.61. The firm’s fifty day moving average price is $10.24 and its two-hundred day moving average price is $12.15. The company has a debt-to-equity ratio of 0.31, a current ratio of 7.09 and a quick ratio of 6.97.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.34). Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. The business had revenue of $44.13 million during the quarter, compared to analyst estimates of $41.14 million. During the same quarter in the previous year, the firm earned ($0.33) EPS. Amicus Therapeutics’s revenue was up 107.1% on a year-over-year basis. On average, analysts expect that Amicus Therapeutics, Inc. will post -1.39 earnings per share for the current year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Read More: How to invest in a bear market

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report